+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?

Journal of Hepatology 56(3): 686-695

Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?

Hepatocellular cancer is a significant global health problem yet the prognosis for the majority of patients has not changed significantly over the past few decades. For patients with advanced disease, sorafenib is currently the standard of care providing a survival advantage of 2-3 months in selected patients. Cytotoxic chemotherapy has been used for over 30 years but definite evidence that it prolongs survival has been lacking. Resistance remains a significant barrier for both targeted and cytotoxic agents and an understanding of the underlying mechanisms is critical if outcomes are to be improved. Here, we summarise the past and current data that constitute the evidence base for chemotherapy in HCC, review the causes of chemoresistance and suggest strategies to overcome these barriers.

Accession: 036221919

PMID: 21971559

DOI: 10.1016/j.jhep.2011.07.031

Related references

Wang, G., 2006: Challenges and opportunities in chemotherapy for hepatocellular carcinoma patients. Zhonghua Gan Zang Bing Za Zhi 14(7): 537-539

Greten, T.F.; Manns, M.P.; Reinisch, I.; Kaatsch, P., 2005: Hepatocellular carcinoma occurring after successful treatment of childhood cancer with high dose chemotherapy and radiation. Sepsis is a systemic inflammatory response to the presence of infection, mediated via the production of many cytokines, including tumour necrosis factor (TNF-), interleukin (IL)-6, and IL-1, which cause changes in the circulation and in the coagul...

Conlin, A.K.; Seidman, A.D., 2008: Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities. As reflected in its varied clinical behavior, appearances under the light microscope, and differential patterns of gene expression, metastatic breast cancer (MBC) is a heterogeneous disease. Systemic treatment decisions are guided by specific tumo...

Pinedo, H.M.; van Groeningen, C.J., 2001: Emerging new opportunities for patients with hepatic metastases from colorectal cancer or primary hepatocellular cancer. Oncologist 6(1): 12-13

Sakai, Y.; Izumi, N.; Tazawa, J.; Yoshida, T.; Sakai, H.; Yauchi, T.; Hattori, K.; Tozuka, S.; Marumo, F.; Sato, C., 1997: Treatment for advanced hepatocellular carcinoma by transarterial chemotherapy using reservoirs or one-shot arterial chemotherapy. A prospective trial was performed in patients with advanced hepatocellular carcinoma to assess the therapeutic efficacy of transcatheter arterial chemotherapy using implanted reservoirs (12 patients) or conventional transcatheter arterial chemothe...

Bleiberg, H., 1996: Role of chemotherapy for advanced colorectal cancer: new opportunities. Since the late 1950s, 5-fluorouracil (5-FU) has remained the most effective chemotherapeutic agent in the treatment of advanced colorectal cancer, although response rates to 5-FU monotherapy are typically no more than 15%. However, efforts at impr...

Sternberg, C.N.; Donat, S.Machele.; Bellmunt, J.; Millikan, R.E.; Stadler, W.; D.M.lder, P.; Sherif, A.; von der Maase, H.; Tsukamoto, T.; Soloway, M.S., 2007: Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. To determine the optimal use of chemotherapy in the neoadjuvant, adjuvant, and metastatic setting in patients with advanced urothelial cell carcinoma, a consensus conference was convened by the World Health Organization (WHO) and the Société Int...

Akhtari, M.; Bernicker, E.H.; Teh, B.S., 2016: Chemotherapy in non-small cell lung cancer: opportunities for advancement. Locally advanced non-small cell lung cancer (NSCLC) continues to be a challenging disease to treat. With high rates of both local and distant failures, there is significant interest in finding more biologically active chemotherapy regimens that ca...

Gentil, F., 1964: Iv. Combination Of Chemotherapy And Surgery In The Treatment Of Cancer. Intra-Arterial Cancer Chemotherapy With Or Without An Isolated Extracorporeal Circuit. Acta - Unio Internationalis Contra Cancrum 20: 57-62

Tsochatzis, E.A.; Germani, G.; Burroughs, A.K., 2010: Transarterial chemoembolization, transarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment. Intra-arterial (IA) therapies for hepatocellular carcinoma (HCC) are considered palliative and should be offered to patients with intermediate-stage multinodular disease and with sufficient liver reserve. They include transarterial chemoembolizati...